Pogled na povijesno otkriće Plivina azitromicina

master's thesis

• Title (english): Overview of historical discoveriy of Pliva's azithromycin
• Author: Marija Zima
• Mentor: Suzana Inić (mentor)
• Committee member: Suzana Inić (predsjednik povjerenstva)
• Committee member: Jasna Jablan (član povjerenstva)
• Committee member: Marijana Zovko Končić (član povjerenstva)
• Granter: University of Zagreb; Faculty of Pharmacy and Biochemistry; Zagreb
• Defense date and country: 2016-09-29, Croatia
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Pharmacy; Pharmacy

Abstract

Ovaj diplomski rad donosi pregled jednog od najvećih otkrića u hrvatskoj kemijskoj znanosti,
sinteze Plivina azitromicina (1981.). Razvoj farmaceutske industrije u Hrvatskoj započinje
osnivanjem dioničarskog društva i tvornice „Kaštel“ (1920.) koja se dvadesetak godina kasnije
spaja s Državnim zavodom za proizvodnju lijekova i vakcina te nastavlja poslovanje pod
današnjim imenom „Pliva“ (1942.). Osnivanjem Plivina istraživačkog instituta (1952.) počinje
znanstveno-istraživački rad s ciljem razvoja novih lijekova. Otkriće azitromicina,
širokosprektralnog makrolidnog antibiotika, najveći je uspjeh u povijesti Plive i hrvatske
farmaceutske industrije. Nastao je kao produkt višegodišnjeg rada na novim kemijskim spojevima,
posebice na derivatima eritromicina A. Za njegovo otkriće zaslužan je istraživački tim
Istraživačkog instituta u Plivi: mr. sc. Gabrijela Kobrehel, dr. sc. Gorjana Lazarevski, dr. sc.
Zrinka Tamburašev s voditeljem dr. sc. Slobodanom Đokićem. Azitromicin je postao osnova za
razvoj novih makrolidnih antibiotika, kasnije nazvanih azalidima kao i za mnogobrojna
istraživanja na području azitromicinske kemije koja su rezultirala velikim brojem Plivinih patenata
i znanstvenih radova. Pliva je gotovi lijek stavila na tržište u sradnji s američkom farmaceutskom
tvrkom Pfizer. Pod zaštićenim imenima Sumamed (Pliva) i Zithromax (Pfizer), azitromicin je
postao jedan od najprodavanijih antibiotika na svjetskoj razini zbog iznimno uspješnog terapijskog
djelovanja.

Abstract (english)

This thesis provides an overview of one of the greatest discoveries of the Croatian chemical
science, synthesis of azithromycin by Pliva (1981). The development of the pharmaceutical
industry in Croatia began with establishment of joint stock company and the company "Kaštel"
(1920), which about twenty years later merged with the National Institute for the production of
medicines and vaccines and continues to operate under its current name "Pliva" (1942). With
establishment of Pliva's Research Institute (1952) began scientific research aimed at developing
new drugs. The discovery of azithromycin, broad-spectrum macrolide antibiotic, is the biggest
success in the history of Pliva and Croatian pharmaceutical industry. It was created as a product of
several years of work on new chemical compounds, in particular the derivatives of erythromycin
A. Its discovery is credited to the research team of the Research Institute Pliva: Gabrijela
Kobrehel, M.Sc., Gorjana Lazarevski, Ph.D., Zrinka Tamburašev, Ph.D., with their research team
leader Slobodan Đokić, Ph.D. Azithromycin has become a basis for the development of new
macrolide antibiotics, later called azalides as well as extensive research in the field of
azithromycin chemistry that resulted in a large number of Pliva patents and scientific papers. Pliva
has put finished drug on the market in partnership with the US pharmaceutical company Pfizer.
Under the brand name Sumamed (PLIVA) and Zithromax (Pfizer), azithromycin has become one
of the best-selling antibiotics on a global level due to the extremely successful therapeutic effects.

• Keywords: azitromicin; Sumamed; Pliva
• Keywords (english): azithromycin; Sumamed; Pliva
• Language: croatian
• URN:NBN: urn:nbn:hr:163:075627
• Study programme: Title: Pharmacy; Study programme type: university; Study level: integrated undergraduate and graduate; Academic / professional title: magistar/magistra farmacije (magistar/magistra farmacije)
• Type of resource: Text
• File origin: Born digital
• Access conditions: Access restricted to students and staff of home institution
• Created on: 2016-12-08 13:53:39